Biogen and Ionis Pharmaceuticals’ Spinraza could be on the US market within weeks after a phase 3 trial in the rare neuromuscular disorder, spinal muscular atrophy, met its goal. The ...

Bristol-Myers Squibb has ended a $3.1 billion strategic collaboration with Eisai focusing on antibody-drug conjugates (ADCs) and returned rights to the lead drug in the alliance. Eisai said in a ...